The selected article could not be found. Try again later or contact administrator.
Interventional/Surgery
Nov 18, 2009 10:45 EST
Measures of left ventricular dysfunction or wall motion identified by different imaging modalities at baseline offer no clues as to whether a subset of patients treated with surgical ventricular reconstruction might benefit from the procedure.

Orlando, FL - Heaping on the disappointment, a new substudy from the Surgical Treatment for Ischemic Heart Failure (STICH) trial has failed to find a subgroup that benefits from surgical ventricular reconstruction (SVR), a least on the basis of left ventricular (LV) function at the time of study enrollment. Read full article »

Inside: Interventional/Surgery
Accredited educational programs, supported by industry, developed by theheart.org

 
heartbriefs
Nov 20, 2009 13:15 EST
As part of his mission to see more financial transparency in medicine, Sen Grassley has asked eight top US medical schools about their policies on ghostwriting.
Medscape Medical News
2 COMMENTS - Nov 20, 2009 13:00 EST
Mayo Clinic researchers report that their stroke rate related to PCI has stayed steady for the last 15 years, something they interpret as good news, given that substantially older, sicker patients with more complex anatomy are now undergoing PCI.
Top Story
Nov 19, 2009 11:00 EST
A dose-finding study saw what were characterized as low bleeding rates associated with triple-drug antithrombotic therapy that included the oral anticoagulant dabigatran in patients with a recent ACS event and other cardiovascular risk factors.
News
Nov 19, 2009 10:00 EST
Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.
Interventional/Surgery
1 COMMENT - Nov 18, 2009 15:45 EST
New data from the BARI 2D trial comparing medical therapy vs revascularization in diabetics shows higher up-front costs of revascularization are only partially offset by long-term savings.
Thrombosis Risk
Nov 18, 2009 15:00 EST
New and unique phase 2 data add to the growing body of evidence explaining the pharmacologic effects of the new antiplatelet agent ticagrelor.
Acute Coronary Syndromes
10 COMMENTS - Nov 18, 2009 09:00 EST
The latest evidence for the treatment of STEMI and PCI has been incorporated into a fast-track update of US guidelines. But questions remain about the quality of some of the evidence informing the guidelines and about the composition of the writing committees.
Interventional/Surgery
Nov 17, 2009 10:00 EST
Mean pericardial effusion grade postcardiac surgery was not reduced with 14 days of treatment with the NSAID.
Interventional/Surgery
4 COMMENTS - Nov 17, 2009 09:00 EST
Dual antiplatelet therapy did not significantly reduce vein graft intimal hyperplasia compared with aspirin alone over 12 months.
Heart failure
Nov 17, 2009 08:00 EST
UPDATED WITH COMMENTARY // Thoratec's HeartMate II continuous-flow VAD keeps about half of patients alive and stroke- or reintervention-free after two years in pivotal destination therapy trial.
Brain/Kidney/Peripheral
Nov 16, 2009 18:45 EST
Depression after coronary artery bypass surgery is often overlooked by physicians but is associated with worse outcomes. A new US study illustrates a simple telephone-based approach to tackle this, with nurses encouraging patients to seek help from their primary-care doctors and providing ongoing feedback and review.
Editorial Programs
Editorial series
3 COMMENTS - Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
Editorial series
Oct 30, 2009 12:35 EDT
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Editorial series
2 COMMENTS - Oct 13, 2009 10:15 EDT
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
button
Previews
Resource center
Poll
Will the best stents of the future have some kind of polymer coating?
See: Stent pioneer Julio Palmaz urges DES makers to "learn from mistakes of the past"
Yes
No

Info from Industry